Riptide Aspiration System (Riptide Large Bore Aspiration System)

K183185 · Micro Therapeutics, Inc. d/b/a ev3 Neurovascular · NRY · Dec 18, 2018 · Cardiovascular

Device Facts

• Record ID: K183185
• Device Name: Riptide Aspiration System (Riptide Large Bore Aspiration System)
• Applicant: Micro Therapeutics, Inc. d/b/a ev3 Neurovascular
• Product Code: NRY · Cardiovascular
• Decision Date: Dec 18, 2018
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 870.1250
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Riptide™ Aspiration System is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.

Device Story

Riptide™ Large Bore Aspiration Tubing serves as a sterile conduit for vacuum transmission from the Riptide™ Aspiration Pump to a distal catheter tip. It connects the non-sterile Riptide™ Canister to the sterile catheter environment. The device features an in-line flow switch for user control of aspiration. Used in clinical settings by physicians for revascularization procedures, the tubing facilitates the removal of thrombi in acute ischemic stroke patients. By enabling vacuum-assisted aspiration, the system aims to restore blood flow in occluded intracranial vessels, potentially improving patient outcomes.

Clinical Evidence

No clinical data. Substantial equivalence is supported by non-clinical bench testing, including dimensional, mechanical, and performance evaluations (vacuum pressure, flow rate, recanalization).

Technological Characteristics

Single-use sterile tubing; biocompatible materials; 112" usable length; 0.110" inner diameter; 0.188" outer diameter; EO sterilization; 36-month shelf life. Features in-line flow switch. Connects to aspiration pump and catheter.

Indications for Use

Indicated for patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (internal carotid, middle cerebral M1/M2, basilar, vertebral arteries) within 8 hours of symptom onset. Candidates include those ineligible for or failing IV t-PA therapy.

Regulatory Classification

Identification

A percutaneous catheter is a device that is introduced into a vein or artery through the skin using a dilator and a sheath (introducer) or guide wire.

Predicate Devices

• Riptide™ Aspiration Tubing (K172448)

Reference Devices

• Arc™ Catheter
• React™ 68 Catheter
• React™ 71 Catheter

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logos of the Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA). The HHS logo is on the left, and the FDA logo is on the right. The FDA logo includes the FDA acronym in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.

December 18, 2018

Micro Therapeutics, Inc. d/b/a ev3 Neurovascular Nancy Drew. PhD Senior Regulatory Affairs Specialist 9775 Toledo Way Irvine, California 92618

Re: K183185

Trade/Device Name: Riptide™ Aspiration System (Riptide™ Large Bore Aspiration Tubing) Regulation Number: 21 CFR 870.1250 Regulation Name: Percutaneous Catheter Regulatory Class: Class II Product Code: NRY Dated: November 16, 2018 Received: November 19, 2018

Dear Nancy Drew, PhD:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's

{1}------------------------------------------------

requirements, including, but not limited to: registration and listing (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely.

Xiaolin Zheng -S

for Carlos L. Peña, PhD, MS Director Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known) K183185

Device Name

Riptide™ Aspiration System (Riptide™ Large Bore Aspiration Tubing)

Indications for Use (Describe)

The Riptide™ Aspiration System is intended for use in the revascularization of patients with acute iscoke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.

| Type of Use (Select one or both, as applicable) | |
|----------------------------------------------------------------------------|---------------------------------------------------------------------------|
| <div> <span>☑</span> Prescription Use (Part 21 CFR 801 Subpart D) </div> | <div> <span>☐</span> Over-The-Counter Use (21 CFR 801 Subpart C) </div> |

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

### 510(k) Summary: K183185

| 510(k) Owner: | Micro Therapeutics, Inc. d/b/a ev3 Neurovascular<br>9775 Toledo Way<br>Irvine, CA 92618<br>Establishment Registration: 2029214 |
|---------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| Contact Person: | Nancy Drew<br>Senior Regulatory Affairs Specialist<br>Telephone: [phone]<br>Email: [e-mail] |
| Date Summary<br>Prepared: | December 13, 2018 |
| Trade Name of<br>Device: | Riptide™ Aspiration System<br>(Riptide™ Large Bore Aspiration Tubing) |
| Common Name of<br>Device: | Catheter, Thrombus Retriever |
| Review Panel: | Neurology |
| Product Code: | NRY |
| Regulation Number: | 21 CFR 870.1250 |
| Regulation Name: | Percutaneous Catheter |
| Device Classification | Class II |

510(k): K172448

## Device Description:

Predicate Device:

The Riptide™ Large Bore Aspiration Tubing is provided sterile and intended for single-use. The Riptide™ Large Bore Aspiration Tubing serves as a conduit to supply vacuum from the Riptide™ Aspiration Pump to the distal tip of the catheter. The Riptide™ Large Bore Aspiration Tubing provides a connection between the sterile and non-sterile environments. The proximal end of the Riptide™ Large Bore Aspiration Tubing is connected to the Riptide™ Canister (outside of the sterile environment) while the distal end of the Riptide™ Large Bore Aspiration Tubing is connected to the catheter (inside the sterile environment). The Riptide™ Canister is connected to the Riptide™ Aspiration Pump (also outside of the sterile environment) via the Intermediate Tubing. The Riptide™ Large Bore Aspiration Tubing is designed to allow the user to control the application via an in-line flow switch.

Riptide™ Aspiration System (Riptide™ Aspiration Tubing)

### Indication for Use Statement:

The Riptide™ Aspiration System is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.

{4}------------------------------------------------

| Device Comparison: | Predicate: Riptide™ Aspiration Tubing (K172448) | Subject: Riptide™ Large Bore Aspiration Tubing |
|------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|
| Indication for Use (IFU) Statement | The Riptide™ Aspiration System is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment | Same |
| Materials | Biocompatible, commonly utilized for interventional devices. | Same |
| Dimensions | | |
| Usable Length | 112.0" | Same |
| Distal Length | 7.0" | Same |
| Inner Diameter | 0.088" | 0.110" |
| Outer Diameter | 0.188" | Same |
| Sterilization | | |
| Method | Ethylene Oxide (EO) | Same |
| Packaging | | |
| Shelf Life | 36 Months | Same |

# Biocompatibility:

Biocompatibility was leveraged for the Riptide™ Large Bore Aspiration Tubing from the predicate device.

## Performance Data – Bench:

Non-clinical bench testing was leveraged and conducted to evaluate the performance of the Riptide™ Large Bore Aspiration Tubing.

The following non-clinical bench testing was leveraged for the Riptide™ Large Bore Aspiration Tubing:

| Test | Test Method Summary | Results |
|--------------------------------------|------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <i>Performance</i> | | |
| Compatibility | Leveraged from predicate device | The Riptide™ Large Bore<br>Aspiration Tubing met the<br>acceptance criteria for<br>compatibility with the Arc™<br>Catheter, React™ 68 Catheter,<br>React™ 71 Catheter, and<br>Riptide™ Collection Canister |
| <i>Microbial</i> | | |
| Test | Test Method Summary | Results |
| Ethylene Oxide (EO) Residual | Leveraged from predicate device | The Riptide™ Large Bore Aspiration Tubing met the acceptance criteria for ethylene oxide residual. |
| Ethylene Chlorohydrin (ECH) Residual | Leveraged from predicate device | The Riptide™ Large Bore Aspiration Tubing met the acceptance criteria for ethylene chlorohydrin residual. |
| Bioburden Recovery | Leveraged from predicate device | The Riptide™ Large Bore Aspiration Tubing met the acceptance criteria for bioburden recovery. |
| Bioburden | Leveraged from predicate device | The Riptide™ Large Bore Aspiration Tubing met the acceptance criteria for bioburden. |
| Bacterial Endotoxin | Leveraged from predicate device | The Riptide™ Large Bore Aspiration Tubing met the acceptance criteria for bacterial endotoxin. |
| Packaging<br>Aseptic Presentation | Leveraged from predicate device | The Riptide™ Large Bore Aspiration Tubing met the acceptance criteria for aseptic presentation. |
| Seal Width | Leveraged from predicate device | The Riptide™ Large Bore Aspiration Tubing met the acceptance criteria for seal width. |
| Dye Leak | Leveraged from predicate device | The Riptide™ Large Bore Aspiration Tubing met the acceptance criteria for dye leak. |
| Visual Inspection | Leveraged from predicate device | The Riptide™ Large Bore Aspiration Tubing met the acceptance criteria for visual inspection. |
| Bubble Leak | Leveraged from predicate device | The Riptide™ Large Bore Aspiration Tubing met the acceptance criteria for bubble leak. |
| Legibility | Leveraged from predicate device | The Riptide™ Large Bore Aspiration Tubing met the acceptance criteria for labeling legibility. |
| Foreign Material | Leveraged from predicate device | The Riptide™ Large Bore Aspiration Tubing met the acceptance criteria for foreign material. |
| Test | Test Method Summary | Results |
| Seal Strength | Leveraged from predicate<br>device | The Riptide™ Large Bore<br>Aspiration Tubing met the<br>acceptance criteria for seal<br>strength. |

{5}------------------------------------------------

{6}------------------------------------------------

The following non-clinical bench testing was conducted:

| Test | Test Method Summary | Results |
|-------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| Dimensional Inspection | The overall and distal length, proximal and distal inner and outer diameter of the Riptide™ Large Bore Aspiration Tubing is measured. | The Riptide™ Large Bore Aspiration Tubing met the acceptance criteria for dimensional inspection. |
| Identification (ON/OFF Heat Shrink Bands) | The heat shrink bands of the Riptide™ Large Bore Aspiration Tubing is visually inspected. | The Riptide™ Large Bore Aspiration Tubing met the acceptance criteria for identification of the heat shrink bands. |
| Identification (Flow Switch) | The flow switch of the Riptide™ Large Bore Aspiration Tubing is visually inspected. | The Riptide™ Large Bore Aspiration Tubing met the acceptance criteria for identification of the flow switch. |
| Joint Tensile Strength | The Riptide™ Large Bore Aspiration Tubing is affixed to upper and lower grips of the tensile test fixture and stretched. The maximum value before failure is recorded. | The Riptide™ Large Bore Aspiration Tubing met the acceptance criteria for joint tensile strength. |
| Leak | The Riptide™ Large Bore Aspiration Tubing is pressurized to specified vacuum pressure and any decay in pressure is recorded. | The Riptide™ Large Bore Aspiration Tubing met the acceptance criteria for leak (vacuum decay). |
| Degree of Collapse | Degree of Collapse for the Riptide™ Large Bore Aspiration Tubing is performed per ISO 10079-3 | The Riptide™ Large Bore Aspiration Tubing met the acceptance criteria for degree of collapse |

In addition, the following non-clinical bench testing was leveraged to evaluate the performance of Riptide™ Aspiration System (Riptide™ Large Bore Aspiration Tubing):

| Test | Test Method Summary | Results |
|----------------|---------------------------------|------------------------------------------------------------------------------------------------------------------------|
| Recanalization | Leveraged from predicate device | The Riptide™ Aspiration System (Riptide™ Large Bore Aspiration Tubing) met the acceptance criteria for recanalization. |

{7}------------------------------------------------

| Test | Test Method Summary | Results |
|----------------------|---------------------------------|------------------------------------------------------------------------------------------------------------------------------|
| Vacuum Pressure | Leveraged from predicate device | The Riptide™ Aspiration System (Riptide™ Large Bore Aspiration Tubing) met the acceptance criteria for vacuum pressure. |
| Volumetric Flow Rate | Leveraged from predicate device | The Riptide™ Aspiration System (Riptide™ Large Bore Aspiration Tubing) met the acceptance criteria for volumetric flow rate. |
| Usability | Leveraged from predicate device | The Riptide™ Aspiration System (Riptide™ Large Bore Aspiration Tubing) met the acceptance criteria for usability. |

# Performance Data - Animal:

A determination of substantial equivalence is based upon non-clinical bench testing as there is no change to the indication for use statement, fundamental scientific technology, or materials of construction.

## Performance Data - Clinical:

A determination of substantial equivalence is based upon non-clinical bench testing as there is no change to the indication for use statement, fundamental scientific technology, or materials of construction.

### Conclusion:

The design modification incorporated into the Riptide™ Large Bore Aspiration Tubing do not alter the indication for use statement, fundamental scientific technology, or materials of construction. In addition, the design modification does not raise new questions on the safety and effectiveness of the device. Therefore, the Riptide™ Large Bore Aspiration Tubing is substantially equivalent to the predicate device.